Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Review

Candida glabrata Chorioamnionitis following in vitro Fertilization: Review of the Literature

Ganer Herman H.a · Mevorach Zussman N.a · Krajden Haratz K.a · Bar J.a, b · Sagiv R.a, b

Author affiliations

aDepartment of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, and bSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Related Articles for ""

Gynecol Obstet Invest 2015;80:145-147

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Review

Received: December 16, 2014
Accepted: May 06, 2015
Published online: June 12, 2015
Issue release date: October 2015

Number of Print Pages: 3
Number of Figures: 0
Number of Tables: 0

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: https://www.karger.com/GOI

Abstract

Aim: To review all past reports of Candida glabrata chorioamnionitis in the literature while noting their correlation with in vitro fertilization (IVF). Methods: We checked MEDLINE, PubMed and Google scholar (January 1970 to December 2014) for articles using the search terms ‘Candida', ‘Torulopsis', ‘glabrata', ‘chorioamnionitis', ‘congenital', ‘perinatal' and ‘infection'. Case reports were included if they described a verified intrauterine infection with C. glabrata. The authors reviewed the articles and abstracted the data. 20 cases were compared, including a case reported from our institution shortly described in this article. Results: 13 of 20 cases (65%) involved pregnancies achieved by IVF; 3 patients underwent amniocentesis during their pregnancy. Of the 7 cases with no history of IVF, 2 involved a history of cerclage and 2 a history of intrauterine device use. Only 6 infants survived, delivered prematurely by cesarean section. Conclusions: Review of literature demonstrated a high prevalence of IVF-assisted pregnancies among the few C. glabrata chorioamnionitis cases previously described, typically occurring during the second trimester. Additional cases were notable for additional instrumentation/invasive procedure. The prognosis was mostly grim, entailing a high incidence of stillbirth or rapid neonatal death.

© 2015 S. Karger AG, Basel


References

  1. Capoccia R, Greub G, Baud D: Ureaplasma urealyticum, Mycoplasma hominis and adverse pregnancy outcomes. Curr Opin Infect Dis 2013;26:231-240.
  2. Fidel PL Jr, Vazquez JA, Sobel JD: Candida glabrata: review of epidemiology, pathogenesis and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999;12:80-96.
    External Resources
  3. Buitrón García-Figueroa R, Araiza-Santibáñez J, Basurto-Kuba E, Bonifaz-Trujillo A: Candida glabrata: an emergent opportunist in vulvovaginitis. Cir Cir 2009;77:423-427.
    External Resources
  4. Wenjin Q, Yifu S: Epidemiological study on vaginal Candida glabrata isolated from pregnant women. Scand J Infect Dis 2006;38:49-54.
  5. Jackel D, Lai K: Candida glabrata sepsis associated with chorioamnionitis in an in vitro fertilization pregnancy: case report and review. Clin Infect Dis 2013;56:555-558.
  6. Sfameni SF, Talbot JM, Chow SL, Brenton LA, Scurry JP: Candida glabrata chorioamnionitis following in vitro fertilization and embryo transfer. Aust NZ J Obstet Gynaecol 1997;37:88-91.
  7. Asemota OA, Nyirjesy P, Fox R, Sobel JD: Candida glabrata complicating in vitro pregnancy: successful management of subsequent pregnancy. Fertil Steril 2011;95:803.e1-2.
  8. Ibara AS, Marcorelles P, Le Martelot MT, Touffet N, Moalic E, Hery-Arnaud G, Giroux JD, Le Flohic AM: Two cases of systemic Candida glabrata infection following in vitro fertilization and embryo transfer. Eur J Clin Microbiol Infect Dis 2004;23:53-56.
  9. Carbonnel M, Kayem G, Luquet-Besson I, Sinico M, Abirached F, Hadad B: Candida glabrata chorioamnionitis following in vitro fertilization. J Gynecol Obstet Biol Reprod 2007;36:705-708.
  10. Salem HM, Balawi M, Sansegundo A, Martinez F, Delgado M, Aparicio JM: Chorioamnionitis from Candida glabrata following in vitro fertilization and embryo transfer. Clin Invest Ginecol Obstet 2000;27:66-67.
  11. Bruner JP, Elliott JP, Kilbride HW, Garite TJ, Knox GE: Candida chorioamnionitis diagnosed by amniocentesis with subsequent fetal infection. Am J Perinatol 1986;3:213-218.
  12. Quirke P, Hwang WS, Validen GC: Congenital Torulopsis glabrata infection in man. Am J Clin Pathol 1980;73:137-140.
    External Resources
  13. Sander CH, Martin JN, Rogers AL, Barr M Jr, Heidelberger KP: Perinatal infection with Torulopsis glabrata: a case associated with maternal sickle cell anemia. Obstet Gynecol 1983;61(suppl 3):21S-24S.
    External Resources
  14. Catanzarite VA, Wilims DC, Holdy KE, Gardner SE, Ludwig DM, Cousins LM: Brain death during pregnancy: tocolytic therapy and aggressive maternal support on behalf of the fetus. Am J Perinatol 1997;14:431-434.
  15. Arai H, Goto R, Matsuda T, Saito S, Hirano H, Sanada H, Sato A, Takada G: Case of congenital infection with Candida glabrata in one infant in a set of twins. Pediatr Int 2002;44:449-450.
  16. Freydiere AM, Piens MA, Andre JM, Putet G, Picot S: Successful treatment of Candida glabrata peritonitis with fluconazole plus flucytosine in a premature infant following in vitro fertilization. Eur J Clin Microbiol Infect Dis 2005;24:704-705.
  17. Matsuzawa S, Ohyama M, Kawataki M, Itani Y, Hashimoto S, Yamanaka M, Ijiri R, Tanaka Y: Congenital Candida glabrata infection without specific nodules on the placenta and umbilical cord. Pediatr Infect Dis J 2005;24:744-745.
  18. Ozer E, Unlu M, Ersen A, Gulekli B: Intrauterine fetal loss associated with Candida glabrata chorioamnionitis: report of two cases. Turk Patoloji Derg 2013;29:77-79.
  19. Tan SQ, Ng OT, Khong CC: Candida glabrata sepsis associated with chorioamnionitis in an IVF twin pregnancy: Should we deliver? J Obstet Gynaecol Res 2014, Epub ahead of print.
  20. Toy EC, Scerpella EG, Riggs JW: Tuboovarian abscess associated with Candida glabrata in a woman with an intrauterine device. A case report. J Reprod Med 1995;40:223-225.
    External Resources
  21. Marelli G, Mariani A, Frigerio L, Leone E, Ferrari A: Fetal Candida infection associated with an intrauterine contraceptive device. Eur J Obstet Gynecol Reprod Biol 1996;68:209-212.
  22. Geisler WM, Wang C, Morrison SG, Black CM, Bandea CI, Hook EW 3rd: The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sex Transm Dis 2008;35:119-123.
  23. Baud D, Regan L, Greub G: Emerging role of Chlamydia and Chlamydia-like organisms in adverse pregnancy outcomes. Curr Opin Infect Dis 2008;21:70-76.
  24. Oakeshott P, Aghaizu A, Hay P, Reid F, Kerry S, Atherton H, Simms I, Taylor-Robinson D, Dohn B, Jensen JS: Is Mycoplasma genitalium in women the ‘New Chlamydia?' A community-based prospective cohort study. Clin Infect Dis 2010;51:1160-1166.
  25. Cicinelli E, De Ziegler D, Nicoletti R, Tinelli R, Saliani N, Resta L, Bellavia M, De Vito D: Poor reliability of vaginal and endocervical cultures for evaluating microbiology of endometrial cavity in women with chronic endometritis. Gynecol Obstet Invest 2009;68:108-115.
  26. Agnani G, Aksoy S, Bresson JL, et al: Infection of the culture media for IVF. Arch STD HIV Res 1992;6:113-116.
  27. Donders GGG, Bellen G, Mendling W: Management of recurrent vulvo-vaginal candidosis as a chronic illness. Gynecol Obstet Invest 2010;70:306-321.

Article / Publication Details

First-Page Preview
Abstract of Review

Received: December 16, 2014
Accepted: May 06, 2015
Published online: June 12, 2015
Issue release date: October 2015

Number of Print Pages: 3
Number of Figures: 0
Number of Tables: 0

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: https://www.karger.com/GOI


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.